PubMed Journals Articles About "RFVIIa Prophylaxis In Children With Hemophilia A And Inhibitors" RSS

16:59 EDT 21st May 2018 | BioPortfolio

RFVIIa Prophylaxis In Children With Hemophilia A And Inhibitors PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest RFVIIa Prophylaxis In Children With Hemophilia A And Inhibitors articles that have been published worldwide.

More Information about "RFVIIa Prophylaxis In Children With Hemophilia A And Inhibitors" on BioPortfolio

We have published hundreds of RFVIIa Prophylaxis In Children With Hemophilia A And Inhibitors news stories on BioPortfolio along with dozens of RFVIIa Prophylaxis In Children With Hemophilia A And Inhibitors Clinical Trials and PubMed Articles about RFVIIa Prophylaxis In Children With Hemophilia A And Inhibitors for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of RFVIIa Prophylaxis In Children With Hemophilia A And Inhibitors Companies in our database. You can also find out about relevant RFVIIa Prophylaxis In Children With Hemophilia A And Inhibitors Drugs and Medications on this site too.

Showing "rFVIIa Prophylaxis Children With Hemophilia Inhibitors" PubMed Articles 1–25 of 10,000+

Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors: A Survey from the Italian Association of Hemophilia Centers (AICE).

The development of neutralizing antibodies (inhibitors) against infused factor VIII currently represents the main complication of replacement therapy in patients with severe hemophilia A. Inhibitors, indeed, particularly high-titer inhibitors (>5 BU/mL), greatly complicate the management of bleeding, exposing patients to an increased morbidity and mortality risk, thus representing a significant burden for physicians of Hemophilia Treatment Centers (HTCs). Although bypassing agents (i.e., activated prothromb...

Optimization of prophylaxis for hemophilia A.

Prophylactic injections of factor VIII reduce the incidence of bleeds and slow the development of joint damage in people with hemophilia. The aim of this study was to identify optimal person-specific prophylaxis regimens for children with hemophilia A.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors.

Emicizumab prophylaxis overcomes factor VIII inhibitors in Hemophilia A.

Modified Primary Prophylaxis in Previously Untreated Patients With Severe Hemophilia A in Iran.

Recently the low-dose tailoring method of primary prophylaxis has been introduced for previously untreated patients with hemophilia A.

Hemlibra's Remarkable Efficacy A Beacon For Hemophilia Patients.

Hemlibra demonstrates how far antibody science has progressed. Genentech's drug, approved late last year, connects two clotting factors to prevent the devastating bleeds in hemophilia patients with inhibitors. The high price may be offset by avoided costs in patients with factor VIII inhibitors.

Novel alternate hemostatic agents for patients with inhibitors: beyond bypass therapy.

Inhibitor formation is among the most severe complications of hemophilia treatment. With a cumulative incidence of ∼30% in those with severe hemophilia A and ∼3% in those with severe hemophilia B, inhibitors are caused by a T-cell response directed against infused coagulation factor; these inhibitors neutralize factor VIII or IX activity and disrupt normal hemostasis. Inhibitor patients become unresponsive to standard factor treatment and, as an alternative, use bypass treatment (eg, recombinant factor ...

Safety of Dexamethasone for Nausea and Vomiting Prophylaxis in Children Receiving Hematopoietic Stem Cell Transplantation.

Many children undergoing hematopoietic stem cell transplantation (HSCT) experience chemotherapy-induced nausea and vomiting (CINV) despite receiving prophylaxis. Guideline-consistent CINV prophylaxis includes dexamethasone, but uncertainty with regard to safety potentially limits the use of dexamethasone in children. We describe immediate adverse events (AEs) attributable to dexamethasone given for CINV prophylaxis to children during HSCT conditioning.

Factor XIII Co-Treatment with Hemostatic Agents in Hemophilia A Increases Fibrin α-Chain Crosslinking.

Hemophilia A results from the absence, deficiency, or inhibition of factor VIII (FVIII). Bleeding is treated with hemostatic agents (FVIII, recombinant activated factor VIIa [rFVIIa], anti-inhibitor coagulation complex [FEIBA], or recombinant porcine FVIII [rpFVIII]). Despite treatment, some patients have prolonged bleeding. Factor XIII-A2 B2 (FXIII) is a protransglutaminase. During clot contraction, thrombin-activated FXIII (FXIIIa) crosslinks fibrin and α2 -antiplasmin, which promotes red blood cell rete...

Bypassing Agents for Bleeding Prophylaxis in Hemophilia B: A Clinical Conundrum?

Correction: Optimization of prophylaxis for hemophilia A.

[This corrects the article DOI: 10.1371/journal.pone.0192783.].

High Rates of Prescribing Antimicrobials for Prophylaxis in Children and Neonates: Results From the Antibiotic Resistance and Prescribing in European Children Point Prevalence Survey.

This study was conducted to assess the variation in prescription practices for systemic antimicrobial agents used for prophylaxis among pediatric patients hospitalized in 41 countries worldwide.

Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study.

Micafungin has a distinct advantage for antifungal prophylaxis in HSCT owing to its better safety profile, specifically in terms of hepatic and renal toxicity. In children, prophylactic micafungin is given as either 1 mg/kg every day or 3 mg/kg every other day.

Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network.

Patients suffering from von Willebrand disease (VWD) have a variety of bleeding symptoms and require both outpatient care for treatment and, in more severe cases, hospitalization.

The spectrum of bleeding in women and girls with haemophilia B.

Although hemophilia B affects 1 in 25,000 males there may be 3 female hemophilia B carriers per affected male. This clinical review highlights the unique challenges faced by hemophilia B carriers including the under-recognition of bleeding symptoms associated with and without FIX deficiency, discrepancies in correlation between genotype and bleeding phenotype and therapeutic considerations utilizing clinical vignettes of common scenarios.

Inhibitors in Hemophilia A: A Pharmacoeconomic Perspective.

Inhibitors in Hemophilia: Treatment Challenges and Novel Options.

Pharmacokinetic drug evaluation of recombinant Factor VIII for the treatment of hemophilia A.

The prevention of bleeding by prophylactic factor replacement is the recommended approach for the treatment of severe hemophilia. Prophylaxis should be individualized to provide the best clinical benefit to each patient. Therefore, a pharmacokinetic approach is crucial. Areas covered: This review aims to concisely describe the basic principles of pharmacokinetics of FVIII, the role of population pharmacokinetic, the available different recombinant FVIII concentrates and the new extended half-life FVIII mole...

Pharmacokinetics of posaconazol in the prophylaxis and treatment of invasive fungal infection in immunocompromised children in a pediatric hospital.

Background There is no consensus on the optimal dosage use of posaconazole (PSC) for invasive fungal infection (IFI) in pediatric patients and normally it is adjusted with drug levels (DLs) ≥ 0.7 μg/ml and ≥ 1.25 μg/ml for prophylaxis and treatment, respectively. Objective To describe the experience of monitoring DLs of PSC in immunocompromised pediatric patients with IFI and to determine if the recommended doses reach CP effective in prophylaxis (≥ 0.7 μg/mL) and treatment (≥ 1.25 μg/mL). Metho...

Two-incision laparoscopic appendectomy for a severe hemophilia A child patient with coagulation factor VII deficiency: Case report and review of literature.

The main complication of patients with severe hemophilia is recurrent bleeding events that usually affected musculoskeletal contractures. And replacement therapy methods were continuously improved to minimize adverse impacts brought by those complications. However, only several cases reported about the appendectomy for hemophilia A. We report a case of acute appendicitis treated by two-incision laparoscopy in a boy with hemophilia A and coagulation factor VII deficiency for the first time.

Impact of Hemophilia B on Quality of Life in Affected Men, Women, and Caregivers - Assessment of Patient-Reported Outcomes in the B-HERO-S Study.

Health-related quality of life (HRQoL) is impaired in patients with hemophilia, however the impact in mild/moderate hemophilia B and affected women is not well characterized.

Reagent substitutions in the Centers for Disease Control and Prevention Nijmegen-Bethesda assay for factor VIII inhibitors.

Quick Search